TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02220296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin 338
Description: Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin 338
Description: Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
Study: NCT01217489

Intervention type: PROCEDURE
Intervention: Breast scan - Electrical Impedance Mammography
Description: Scanning of the breast on a non-invasive device, using harmless minute electrical currents
Study: NCT02546154

Intervention type: DRUG
Intervention: 10% Iron Isomaltoside 1000
Description: Standard clinical practice and following the Monofer® label (SPC)

Intervention type: DRUG
Intervention: 10% Iron Isomaltoside 1000
Description: Standard clinical practice and following the Monofer® label (SPC)
Study: NCT01759069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment with microscope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment with microscope
Study: NCT01532817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlphaCore
Description: A single 90 second stimulation to the vagus nerve on the right side of the neck
Study: NCT05637411

Intervention type: OTHER
Intervention: Predictive model
Description: We will define and validate predictive models of risk of exacerbations in asthmatic patients

Intervention type: OTHER
Intervention: Predictive model
Description: We will define and validate predictive models of risk of exacerbations in asthmatic patients
Study: NCT03207217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based training Product
Description: A series of 4 modules to train providers to more effectively manage patients who screen positive for risk of suicide. The modules are: Risk Assessment, Safety Planning, Access to Lethal Means, and Willingness to accept referral.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based training Product
Description: A series of 4 modules to train providers to more effectively manage patients who screen positive for risk of suicide. The modules are: Risk Assessment, Safety Planning, Access to Lethal Means, and Willingness to accept referral.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based training Product
Description: A series of 4 modules to train providers to more effectively manage patients who screen positive for risk of suicide. The modules are: Risk Assessment, Safety Planning, Access to Lethal Means, and Willingness to accept referral.
Study: NCT02899364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: see description under experimental arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: see description under placebo comparator arm

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: primary percutaneous coronary intervention
Description: Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary percutaneous coronary intervention
Description: Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cardiac magnetic resonance imaging
Description: CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac magnetic resonance imaging
Description: CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.
Study: NCT03716544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplification with hearing aid
Description: Use of hearing aids

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Customized music
Description: Customized music delivered via an iPod
Study: NCT01803295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40 mg MMC gel
Description: A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care MMC mixed with water
Description: Standard of care 40mg MMC mixed with water

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 80 mg MMC gel
Description: A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
Study: NCT01167283

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrostimulation
Description: Electrostimulation: 35 Hz, 0.4 ms, 1 h; 5 times/week

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation: 1 h; 5 times/week
Study: NCT02019784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin-α
Description: Rifaximin-α will be compared to placebo with the various outcome measures assessed at baseline (pre-randomisation), and then at 30 days and 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study: NCT03072225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal Medicine C-117
Description: Herbal Medicine C-117 formula including 2 herbals and 2 insects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The Placebo of Herbal Medicine C-117
Description: The Placebo of Herbal Medicine C-117 formula including 4 herbals
Study: NCT04334421

Intervention type: DEVICE
Intervention: Composite mesh
Description: Pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) to improve healing and prevent perineal herniation.
Study: NCT01241253

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Whole cooked beans with rice meals
Description: Three types of bean-and-rice meals all equal to 50 grams available CHO. Control treatment was 50 grams available CHO in the form of white rice alone.
Study: NCT04607824

Intervention type: BEHAVIORAL
Intervention: Duchenne Muscular Dystrophy group
Description: Assessment of heart rate variability at rest and during computational task in people with Duchenne muscular dystrophy

Intervention type: BEHAVIORAL
Intervention: Typical Development group
Description: Assessment of heart rate variability at rest and during computational task in people with typical Development
Study: NCT02355522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KY jelly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KY jelly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intrauterine normal saline
Study: NCT00538096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: 1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: 1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-538
Description: 1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
Study: NCT00988221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab was supplied as a sterile solution in vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab was supplied as a sterile solution in vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab was supplied as a sterile solution in vials.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to tocilizumab was supplied as a sterile solution in vials.
Study: NCT04229030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RZL-012
Description: small synthetic molecule for the treatment of Dercum's Disease lipomas

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of RZL-012 drug product
Study: NCT03337191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: % 0,125 levobupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: % 0,125 levobupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: 10 mq/kg morphine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: 10 mq/kg morphine sulfate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided caudal block
Study: NCT00864526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
Description: A: Experimental SSubjects received Actavis formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMBONOX® tablets, single dose
Description: B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
Study: NCT02152501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Energy Expenditure 300 kcal/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Energy Expenditure 600 kcal/day
Study: NCT02354859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gallium nitrate
Description: Study subjects will receive an infusion of either placebo or gallium nitrate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
Study: NCT03008421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astarte® (HSO Health Care GmbH, Vienna, Austria)
Description: oral intake of Astarte® (HSO Health Care GmbH, Vienna, Austria) as described

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical-looking oral potato-maltodextrin-based placebo
Study: NCT05406960

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea infusion
Description: Herbal tea infusion will be administrated by the oral route before food
Study: NCT04997044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concomitant physical rehabilitation
Description: Children of this group will receive a regular exercise rehabilitation program including starching exercises, functional strength training and static and dynamic balance exercises.The program will be conducted by six licensed pediatric physical therapists for one hour/session, 3 times/week, and six successive months.

Intervention type: OTHER
Group type: OTHER
Intervention: Concomitant physical rehabilitation
Description: Children of this group will receive a regular exercise rehabilitation program including starching exercises, functional strength training and static and dynamic balance exercises.The program will be conducted by six licensed pediatric physical therapists for one hour/session, 3 times/week, and six successive months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Orthotic Management
Description: A custom-made articulating ankle foot orthosis was prescribed with a hinge at the level of the medial malleolus extends distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured straps. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Orthotic Management
Description: A custom-made articulating ankle foot orthosis was prescribed with a hinge at the level of the medial malleolus extends distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured straps. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selective dorsal rhizotomy
Description: The surgical procedures were tailored to each child according to preoperative assessment plan. All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact.
Study: NCT02384317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: CCX168 30 mg, twice daily (b.i.d.) orally for 84 days (12 weeks). The CCX168 dose was taken in the morning, optimally within one hour after breakfast, and in the evening, optimally within one hour after dinner.
Study: NCT04597502

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Terminalia Chebula fruit extract
Description: Oral TC fruit extract supplement taken by mouth twice per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Terminalia Chebula fruit extract
Description: Oral TC fruit extract supplement taken by mouth twice per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo taken by mouth twice per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo taken by mouth twice per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Terminalia Chebula
Description: Applied to both forearms and dorsal hands

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Terminalia Chebula
Description: Applied to both forearms and dorsal hands

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo
Description: Applied to both forearms and dorsal hands

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Placebo
Description: Applied to both forearms and dorsal hands
Study: NCT01537679

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Kirtan Kriya meditation
Description: Meditation will be taught to 20 caregivers and supervised by Helen Lavretsky, M.D during their first visit. Meditation Kirtan Kriya will be performed for 12 minutes every day at the same time of the day for 8 weeks. Compliance will be monitored during visits and by daily diaries that will be reviewed at each visit.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation
Description: Participants in the relaxation group will be asked to relax in a quiet place with eyes closed while listening to the music on the relaxation CD for 12 minutes every day at the same time for 8 weeks.
Study: NCT03389607

Intervention type: DIAGNOSTIC_TEST
Intervention: spinal anesthesia
Description: before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation SCUBE-1, MDA and TAC will measured from plasma

Intervention type: DIAGNOSTIC_TEST
Intervention: spinal anesthesia
Description: before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation SCUBE-1, MDA and TAC will measured from plasma
Study: NCT02014090

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic and biological measurements
Description: by MCE, PWA, Doppler, Multiplex, FACS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic and biological measurements
Description: by MCE, PWA, Doppler, Multiplex, FACS
Study: NCT03247374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProComp5 Infiniti Biofeedback
Description: Each participant will attend 5 sessions per week for a total duration of 5 weeks. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The computer will produce visual feedback of the muscular activity on the screen. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: they are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The experimental group will perform this training for 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Speech and Language Therapy
Description: Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy receiving verbal feedback from the speech and language therapist. They are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The control group will perform this training for 45 minutes.
Study: NCT03088358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TeaRx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TeaRx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TeaRx

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Study: NCT02252458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT02761174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine
Description: Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control

Intervention type: OTHER
Group type: OTHER
Intervention: IPL+air-cooling
Description: IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling
Study: NCT00068874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills and cognitive restructuring techniques
Description: This is a cognitive psychoeducational program designed to enhance coping and adaptation to SLE. Participants will attend five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational training
Description: Participants will attend five study visits that will include disease-appropriate education materials.
Study: NCT04311749

Intervention type: GENETIC
Intervention: Umbilical cord blood
Description: Post-delivery umbilical cord blood sampling
Study: NCT03492671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg
Description: Pre-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Pre-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy.
Study: NCT01241877

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: astaxanthin
Description: astaxanthin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03812770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Oral Sorafenib, 400mg, Bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Oral Sorafenib, 400mg, Bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAIC of FOLFOX
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC of OXA
Description: administration of Oxaliplatin via the tumor feeding arteries
Study: NCT03212092

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin, mineral & n-3 FA
Description: The 2 multi vitamin capsules with the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo of the multi vitamin capsules and the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered